Please use this identifier to cite or link to this item:
|Title:||Intragastric administration of Lactobacillus casei expressing transmissible gastroentritis coronavirus spike glycoprotein induced specific antibody production||Authors:||Ho, P.S.
|Issue Date:||3-Feb-2005||Citation:||Ho, P.S., Kwang, J., Lee, Y.K. (2005-02-03). Intragastric administration of Lactobacillus casei expressing transmissible gastroentritis coronavirus spike glycoprotein induced specific antibody production. Vaccine 23 (11) : 1335-1342. ScholarBank@NUS Repository. https://doi.org/10.1016/j.vaccine.2004.09.015||Abstract:||Lactobacillus casei strain Shirota was selected as a bacterial carrier for the development of live mucosal vaccines against coronavirus. A 75 kDa fragment of transmissible gastroenteritis coronavirus (TGEV) spike glycoprotein S was used as the model coronavirus antigen. The S glycoprotein was cloned into a Lactobacillus/E. coli shuttle vector (pLP500) where expression and secretion of the glycoprotein S from the recombinant lactobacilli was detected via immunoblotting. Oral immunization of BALB/c mice with recombinant LcS that constitutively expresses the 75 kDa fragment of the glycoprotein S, induced both local mucosal and systemic immune responses against TGEV. Maximum titers of IgG (8.38 ± 0.19 ng/ml of serum) and IgA (64.82 ± 2.9 ng/ml of intestinal water) were attained 32 days post oral inturbation. The induced antibodies demonstrated neutralizing effects on TGEV infection. © 2004 Elsevier Ltd. All rights reserved.||Source Title:||Vaccine||URI:||http://scholarbank.nus.edu.sg/handle/10635/131546||ISSN:||0264410X||DOI:||10.1016/j.vaccine.2004.09.015|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.